JPMorgan Chase & Co. Issues Pessimistic Forecast for BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Price

Key Points

• JPMorgan cut its BioMarin price target from $87 to $86 but maintained an “overweight” rating; the new target implied about 51% upside from the prior close.
• BioMarin reported quarterly EPS of $0.23, beating estimates of a $0.05 loss, while revenue of about $1.02 billion matched expectations and rose 32% year over year.
• The company lowered its 2026 outlook, forecasting EPS of $2.80–$3.10, below the $3.32 consensus, and revenue of $3.8–$3.9 billion.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) had its target price decreased by JPMorgan Chase & Co. from $87.00 to $86.00 in a report released on Wednesday, Benzinga reports. The firm currently has an "overweight" rating on the biotechnology company's stock. JPMorgan Chase & Co.'s target price points to a potential upside of 50.89% from the stock's previous close.

BMRN has been the topic of several other reports. Weiss Ratings lowered shares of BioMarin Pharmaceutical from a "sell (d+)" rating to a "sell (d)" rating in a research note on Friday, September 18th. BMO Capital Markets restated an "outperform" rating on shares of BioMarin Pharmaceutical in a research note on Wednesday, September 16th. William Blair upgraded BioMarin Pharmaceutical to a "hold" rating in a report on Wednesday, September 23rd. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of BioMarin Pharmaceutical in a research report on Tuesday. Finally, Canaccord Genuity Group upped their target price on BioMarin Pharmaceutical from $111.00 to $114.00 and gave the stock a "buy" rating in a report on Monday, August 10th. Three analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, BioMarin Pharmaceutical currently has an average rating of "Moderate Buy" and a consensus target price of $87.91.

BioMarin Pharmaceutical Stock Up 2.4%

NASDAQ BMRN traded up $1.33 during trading on Wednesday, hitting $56.99. The stock had a trading volume of 1,333,890 shares, compared to its average volume of 2,121,643. BioMarin Pharmaceutical has a 12 month low of $49.26 and a 12 month high of $70.98. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.32 and a current ratio of 2.39. The company's 50-day moving average price is $60.24 and its two-hundred day moving average price is $58.45. The company has a market capitalization of $11.03 billion, a PE ratio of -566.70, a P/E/G ratio of 0.63 and a beta of 0.21.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last posted its quarterly earnings data on Monday, November 2nd. The biotechnology company reported $0.23 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.05) by $0.28. BioMarin Pharmaceutical had a negative net margin of 0.52% and a positive return on equity of 5.59%. The company had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.02 billion. During the same period last year, the company earned $0.12 earnings per share. The firm's revenue was up 32.0% compared to the same quarter last year. As a group, sell-side analysts forecast that BioMarin Pharmaceutical will post 2.59 EPS for the current year.

Institutional Investors Weigh In On BioMarin Pharmaceutical

A number of institutional investors and hedge funds have recently modified their holdings of the company. Parkside Financial Bank & Trust boosted its position in shares of BioMarin Pharmaceutical by 70.3% during the 2nd quarter. Parkside Financial Bank & Trust now owns 453 shares of the biotechnology company's stock worth $26,000 after acquiring an additional 187 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in BioMarin Pharmaceutical in the second quarter valued at approximately $39,000. Keating Financial Advisory Services Inc. bought a new position in BioMarin Pharmaceutical in the second quarter valued at approximately $56,000. Root Financial Partners LLC acquired a new position in BioMarin Pharmaceutical during the third quarter valued at approximately $88,000. Finally, Parallel Advisors LLC raised its position in BioMarin Pharmaceutical by 33.9% during the first quarter. Parallel Advisors LLC now owns 1,768 shares of the biotechnology company's stock valued at $100,000 after purchasing an additional 448 shares in the last quarter. 98.71% of the stock is owned by institutional investors.

Key BioMarin Pharmaceutical News

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: Third-quarter revenue rose 32% year over year to $1.025 billion, in line with estimates, while earnings per share of $0.23 beat expectations. Growth was led by metabolic conditions, up 44%, and skeletal conditions, up 12%. Read More.
• Positive Sentiment: VOXZOGO remains a potential growth catalyst: BioMarin expects an FDA decision on its use for hypochondroplasia by May 30, 2027, which could expand its skeletal-disease franchise. The company also recently added an investigational Fabry asset. Read More.
• Positive Sentiment: An Seeking Alpha analysis argues that BMRN’s lower valuation, broader commercial portfolio and potential product expansion improve its risk-reward profile, while noting that the benefits of the Amicus acquisition still need to justify its financing costs. Read More.
• Neutral Sentiment: BioMarin plans to present at three investor conferences in November, providing management opportunities to discuss results and outlook. Read More.
• Negative Sentiment: The company lowered its full-year 2026 outlook: revenue is now forecast at $3.8–$3.9 billion, versus the $3.9 billion consensus, and EPS at $2.80–$3.10, below the $3.32 consensus. BioMarin cited order-timing uncertainty and charges for acquired in-process research and development, making the guidance cut a key near-term headwind. Read More.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening rare diseases. The company's research and development efforts center on genetic and metabolic disorders, where patient populations are often small and treatment options are limited.

BioMarin's marketed products include Voxzogo (vosoritide) for children with achondroplasia and open growth plates, Palynziq (pegvaliase) and Kuvan (sapropterin dihydrochloride) for phenylketonuria, Brineura (cerliponase alfa) for late-infantile neuronal ceroid lipofuscinosis type 2, Vimizim (elosulfase alfa) for Morquio A syndrome, and Naglazyme (galsulfase) for mucopolysaccharidosis VI.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.